#Canada #Aurora Cannabis #Edmonton #medical cannabis #Q2 Results

Aurora Cannabis Reports Fiscal 2026 Q2 Results

Aurora Cannabis Inc., a leading global player in the medical cannabis market, recently released its financial results for the second quarter of fiscal 2026, which concluded on September 30, 2025. The company reported impressive gains, highlighting strong growth in its global medical cannabis sector. With a year-over-year increase of 15%, the net revenue from medical cannabis reached a record high of $70.5 million.

Key Financial Highlights

In addition to the remarkable performance in the medical cannabis segment, Aurora also noted a significant rise in international medical cannabis revenue, which surged by 22%, totaling $42.7 million. Overall, the consolidated revenue for the quarter stood at $90.4 million, compared to $81.1 million from the previous year, marking an 11% increase. The company experienced a substantial rise in adjusted EBITDA, which grew by 52% to reach $15.4 million.

Executive Chairman and CEO Miguel Martin attributed these results to a disciplined strategy focused on world-class manufacturing, cutting-edge genetics, and deep regulatory expertise, enabling Aurora to maintain its leadership positions in Canada and other key international markets.

Detailed Revenue Breakdown

The medical cannabis arm comprised 78% of Aurora's total consolidated revenue, signifying its dominance in the company’s portfolio. Growth was primarily driven by increased sales to countries such as Australia, Germany, Poland, and the UK, alongside heightened demand domestically, especially from insurance-covered and self-paying patients. The adjusted gross margin for the medical cannabis division was recorded at an impressive 69%, slightly up from 68% in the previous quarter, showcasing improved operational efficiencies.

Conversely, the consumer cannabis segment faced challenges, with reported net revenue declining by 34% to $6.9 million. This decrease was primarily attributed to the company’s strategic choice to allocate more resources to the higher-margin medical cannabis sector. Adjusted gross margins in this segment improved from 15% to 27% year-over-year, due to cost-saving measures.

Meanwhile, the plant propagation business reported a 34% growth, registering $11.6 million in revenue, driven by organic expansion and increased product offerings resulting from enhanced capacity. However, gross margins in this segment saw a decline, impacted by inventory write-offs and unsold surplus crops.

Looking Ahead

Aurora anticipates continued growth in the upcoming fiscal quarters, with expectations of consolidated net revenue rising by 8% to 12% in the global medical cannabis segment. The company is well-positioned with a robust cash reserve of $141.9 million and a nearly debt-free business model, allowing for sustained investment in innovation and production capacity. Martin stated, "Our focus remains on delivering strong outcomes for our shareholders while driving profitable growth across our operations."

Aurora is not just a cannabis company but a transformative force in the industry, keen on improving people’s lives through its quality-driven approach and forward-thinking strategies. Established in Edmonton, Alberta, Aurora continues to expand its footprint across various global markets, emphasizing the significance of medical cannabis in today's healthcare landscape.

In conclusion, with solid growth metrics and strategic investments in infrastructure, Aurora Cannabis is poised for a promising future, strengthening its position as a leader in the medical cannabis sector. The upcoming Q3 is anticipated to reflect positive trends, ensuring Aurora remains a key player in the evolving cannabis landscape.

Contact Information:
For more details about Aurora Cannabis, visit www.auroramj.com or follow them on their social media platforms.